We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Seeking Biomarkers that Predict Immunotherapy Success

Seeking Biomarkers that Predict Immunotherapy Success content piece image
Photo credit: Pixabay
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

The National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG recently announced a collaboration to utilize Protagen’s Cancer Immunotherapy Array to identify biomarkers that predict therapeutic response and the incidence of immune-related adverse events (irAEs) in urothelial carcinoma patients treated with checkpoint inhibitors.

In recent years, checkpoint inhibitors have changed treatment paradigms in cancer. They offer an enormous potential in many indications, including melanoma, lung, and urothelial carcinoma.

Yet, two challenges remain: only a subset of patients respond to treatment, and checkpoint inhibitors trigger (often severe) immune-related Adverse Events (irAEs).

Through this collaboration, Protagen and the NCT Heidelberg will utilize Protagen's Cancer Immunotherapy Array to address these challenges.

Prof. Carsten Grüllich from the NCT Heidelberg, stated:

“Checkpoint inhibitors offer the chance to significantly improve overall survival for cancer patients, and can potentially even cure cancer in some cases. In urothelial carcinoma especially, they can be very successful in a subset of patients, however certain subsets suffer from drug-related toxicities. This makes it vital that we understand better which patients are likely to respond and/or suffer from irAEs. Utilizing Protagen’s Cancer Immunotherapy Array will enable us to establish an immune-profile for each patient, meaning we can assess their immuno-competence to help fight their cancer.”
Dr. Peter Schulz-Knappe, Protagen’s Chief Scientific Officer, commented:

“Our unique Cancer Immunotherapy Array has already demonstrated its potential in malignant melanoma and prostate cancer patients. The extension into urothelial carcinoma is our next step into an indication where cancer immunotherapies have been successful, but also face significant response and toxicity challenges. We believe that applying our technology will result in improved patient selection for novel immunotherapies and better management of risks associated with therapy. We feel privileged that Prof. Grüllich and the NCT Heidelberg share this vision, and are excited about the collaboration.”
This article has been republished from materials provided by Protagen. Note: material may have been edited for length and content. For further information, please contact the cited source.